Lovastatin protects neurite degeneration inLRRK2-G2019Sparkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity

Lovastatin Induces Neuroprotection Through Tumor Necrosis Factor Receptor 2 Signaling Pathways

(2017) Amalia M. Dolga et al.   JOURNAL OF ALZHEIMERS DISEASE

Pretreatment with Lovastatin Prevents N-Methyl-D-Aspartate-Induced Neurodegeneration in the Magnocellular Nucleus Basalis and Behavioral Dysfunction

(2017) Amalia M. Dolga et al.   JOURNAL OF ALZHEIMERS DISEASE

LRRK2 Pathways Leading to Neurodegeneration

(2015) Mark R. Cookson   Current Neurology and Neuroscience Reports

I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway

(2015) Etsuro Ohta et al.   HUMAN MOLECULAR GENETICS

Lrrk regulates the dynamic profile of dendritic Golgi outposts through the golgin Lava lamp

(2015) Chin-Hsien Lin et al.   JOURNAL OF CELL BIOLOGY

Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson’s Disease

(2014) Ian Martin et al.   CELL

Genetic dissection reveals that Akt is the critical kinase downstream of LRRK2 to phosphorylate and inhibit FOXO1, and promotes neuron survival

(2014) Chia-Lung Chuang et al.   HUMAN MOLECULAR GENETICS

Statins and Neuroprotection: Basic Pharmacology Needed

(2014) W. Gibson Wood et al.   MOLECULAR NEUROBIOLOGY

Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice

(2014) Dayne A. Beccano-Kelly et al.   Frontiers in Cellular Neuroscience

Genetics and genomics of Parkinson’s disease

(2014) Michelle K Lin et al.   Genome Medicine

Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β

(2013) Fumitaka Kawakami et al.   FEBS Journal

A Direct Interaction between Leucine-rich Repeat Kinase 2 and Specific β-Tubulin Isoforms Regulates Tubulin Acetylation

(2013) Bernard M. H. Law et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discontinuation of statin therapy associates with Parkinson disease: A population-based study

(2013) Y.-C. Lee et al.   NEUROLOGY

RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk

(2013) David A. MacLeod et al.   NEURON

LRRK2 and vesicle trafficking

(2012) Giovanna Sanna et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Lovastatin Modulates Glycogen Synthase Kinase-3β Pathway and Inhibits Mossy Fiber Sprouting after Pilocarpine-Induced Status Epilepticus

(2012) Chun-Yao Lee et al.   PLoS One

Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2

(2011) David Ramonet et al.   PLoS One

LRRK2 Parkinson’s disease: from animal models to cellular mechanisms

(2011) Chin-Hsien Lin et al.   REVIEWS IN THE NEUROSCIENCES

Simvastatin lowers reactive oxygen species level by Nrf2 activation via PI3K/Akt pathway

(2010) Dionysios Chartoumpekis et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

MKK6 binds and regulates expression of Parkinson’s disease-related protein LRRK2

(2010) Cindy H. Hsu et al.   JOURNAL OF NEUROCHEMISTRY

LRRK2 G2019S Mutation Induces Dendrite Degeneration through Mislocalization and Phosphorylation of Tau by Recruiting Autoactivated GSK3 

(2010) C.-H. Lin et al.   JOURNAL OF NEUROSCIENCE

Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice

(2010) B. Winner et al.   NEUROBIOLOGY OF DISEASE

Genetic Analysis of Pathways to Parkinson Disease

(2010) John Hardy   NEURON

A comparative study of Lrrk2 function in primary neuronal cultures

(2010) Justus C. Dächsel et al.   PARKINSONISM & RELATED DISORDERS

Leucine-Rich Repeat Kinase 2 Mutations and Parkinson's Disease: Three Questions

(2009) Elisa Greggio et al.   ASN Neuro

Lovastatin ameliorates α-synuclein accumulation and oxidation in transgenic mouse models of α-synucleinopathies

(2009) Andrew O. Koob et al.   EXPERIMENTAL NEUROLOGY

RTP801 Is Induced in Parkinson's Disease and Mediates Neuron Death by Inhibiting Akt Phosphorylation/Activation

(2009) C. Malagelada et al.   JOURNAL OF NEUROSCIENCE

Dopamine D1 receptor activation induces tau phosphorylation via cdk5 and GSK3 signaling pathways

(2009) Manon Lebel et al.   NEUROPHARMACOLOGY

Akt signal transduction dysfunction in Parkinson's disease

(2009) Suzanne Timmons et al.   NEUROSCIENCE LETTERS

Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease

(2009) Eugénie Mutez et al.   PHARMACOLOGICAL RESEARCH

CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity

(2009) Han Seok Ko et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice

(2008) Dick Terwel et al.   AMERICAN JOURNAL OF PATHOLOGY

Trends in Statin Use and Low-Density Lipoprotein Cholesterol Levels Among US Adults: Impact of the 2001 National Cholesterol Education Program Guidelines

(2008) Devin Mann et al.   ANNALS OF PHARMACOTHERAPY

Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide

(2008) María del Carmen Hernández-Romero et al.   JOURNAL OF NEUROCHEMISTRY

Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells

(2008) Edward D. Plowey et al.   JOURNAL OF NEUROCHEMISTRY

Statins reduce neuronal α-synuclein aggregation in in vitro models of Parkinson’s disease

(2008) Pazit Bar-On et al.   JOURNAL OF NEUROCHEMISTRY

Mevastatin accelerates loss of synaptic proteins and neurite degeneration in aging cortical neurons in a heme-independent manner

(2008) Madhuvanthi Kannan et al.   NEUROBIOLOGY OF AGING

Statin use and the risk of Parkinson disease

(2008) A. D. Wahner et al.   NEUROLOGY